Rankings Pharma & medtech ChemoMetec
ChemoMetec
73
15070100
A view of the same findings, not a new score. How it works
A strong score: the model found few serious problems, but analysts see limited upside from here.
Biggest deductions
- Absolute price level−6
- Quality of growth−5
- Customers and end market−4
Strengths
- Pricing power and margin+3
- Net cash+2
- Buybacks+1
How the score is built
From 100 to 73, step by step: points off for the business, the price and the cracks, back for documented strengths, then three data adjustments.
Start
Score
Hover or select a step to see what drove it. Steps with findings open them below.
Key numbers
As of 3 Nov 2026. Analyst targets tend to be optimistic; read upside as a hint, not a forecast.
- Price
- 606.00 DKK
- Median analyst target
- 680.00 DKK
- Upside to median
- +12.2%
- Analysts
- 3
- Target range
- 640.00 – 735.00 DKK
- 52-week change
- −22%
- P/E (trailing)
- 52.2
- Forward P/E
- 46.5
- PEG
- n/a
Findings
Every deduction and every plus, with its source. Open a step to read them.
Business
Is the company getting stronger, not just bigger? · 3 findings−9 of −30
- −5Quality of growthRevenue has only grown from DKK 428m to 511m from 2021/22 to 2025/26 (about 4.5% a year) and rose 3% in 2025/26; consumables – the recurring revenue – fell 4%, and the US/Canada (54%) fell 6%.
- −2ROIC trendROIC has fallen from 117% in 2021/22 and 94% in 2022/23 to about 50% in 2025/26 – still far above WACC (11.9%), but capital is growing faster than earnings (inventory, instrument development).
- −2Niche dependenceThe whole business is cell counting for cell and gene therapy and bioproduction (174 employees, DKK 511m). Management talks of 'significant market changes' towards automation, and new partnerships (Roche, Tecan, Hamilton) have no orders yet.
Price
Today's multiples against the company's own history and its peers. · 3 findings−12 of −35
- −3Multiples vs own historyP/E 45 and EV/EBITDA 32.7 are mid-range of its own history (P/E 31–83 and EV/EBITDA 23–60 in 2021/22–2025/26), but above the level at fiscal year-end (P/E 31.2) – the history itself is extremely high.
- −3PeersForward P/E 41.8 vs Sartorius Stedim 39.4, Thermo Fisher 25.8 and Revvity 26.7; EV/EBITDA 32.7 vs 22–28. A premium to all peers, but with a far higher margin.
- −6Absolute price levelFCF yield 2.0% and earnings yield 2.25% at a P/S of 17.6, while guidance for 2026/27 only promises 7–13% revenue growth and EBITDA of DKK 300–315m (+7–12%).
Cracks
Cash flow, customers, debt, insiders, guidance and what sits behind the headline numbers. · 3 findings−9 of −35
- −4Customers and end marketNIH cuts have led to cancelled trials, and Novo Nordisk, Galapagos and Takeda have closed cell and gene therapy programmes. Some of the largest US customers have lower activity, and the US government shutdown in autumn 2025 hit spending.
- −3Execution and guidance credibilityThe year before, the company fell short of its own guidance, so management now guides on a 'worst case' scenario; the stock fell 6.2% on the annual report in September.
- −2CurrencyThe US/Canada is 54% of revenue: sales fell 6% in DKK vs +1% at constant currency, because the weak dollar weighs; costs are in Denmark.
Plus
Only documented strengths. · 3 findings+6 of +15
- +3Pricing power and marginGross margin 95% and EBITDA margin 55% (up from 52%); FCF margin 36%. Few instrument companies earn that much per krone of revenue.
- +2
- +1BuybacksBuybacks of up to DKK 100m (May–October 2026) instead of a dividend; in 2025/26 DKK 122m was paid in dividends and 39m bought back – in total below FCF of 182m.
Caveats
What the score does not capture, or where the data is weak.
Fiscal year ends 30 June (TTM = 2025/26). Only 3 analysts. Cell counters for bioproduction do not fit neatly in the industry list; placed under Pharma & medtech. Insider trades and top customers' share have not been found
Also in Pharma & medtech
The highest scores in the same industry.
